Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon

Condition:   Atrial Fibrillation Interventions:   Drug: Phenprocoumon;   Drug: Apixaban;   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Edoxaban Sponsors:   Bayer;   Janssen Research & Development, LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials